Is Fam-trastuzumab deruxtecan-nxki a targeted drug?

Fam-trastuzumab deruxtecan-nxki is a antibody-drug conjugate (ADC) that targets HER2 cancers. It has two parts, a humanized anti-HER-2 monoclonal antibody and a topoisomerase inhibitor payload "deruxtecan," which are covalently linked via a tetrapeptide-based cleavable linker. Once bound to the HER-2 receptor on a tumor cell, the cell internalizes the antibody along with bound deruxtecan, and adapter cleavage occurs via lysosomal enzymes that release deruxtecan. When released, it impairs the cell's ability to replicate during cell division, causes DNA damage and leads to apoptotic cell death.

Trastuzumab is only available by prescription,it should be prescribed by a doctor and under the supervision of a health care professional experienced in the use of cancer drugs. Trastuzumab is given as a 90-minute intravenous infusion (drip) once every three weeks. Patients who tolerate the first 90-minute infusion may receive subsequent infusions over 30 minutes. Treatment can be continued as long as the treatment is still effective. The dosage is based on the patient's weight and the type of cancer being treated. Infusions may cause allergic reactions, so patients should be monitored for symptoms such as fever and chills during and after the infusion.

Trastuzumab is a new type of injectable anti-cancer drug. The original drug has been launched in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase method is difficult. The Hong Kong version of TrastuzumabSpecifications100mg may cost more than 10,000 yuan per box, and the Hong Kong original versionTrastuzumabOriginal drug specificationsThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to exchange rate effects). The drug ingredients of the two are basically the same. There is currently no generic drug of Trastuzumab produced and launched. For more specific prices and drug information, please consult the medical consultant of the drug.